Category: News

Post

SCYNEXIS Announces Hansoh Pharma’s Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)

SCYNEXIS Announces Hansoh Pharma’s Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC) Submission is part of the Hansoh Pharma licensing agreement and strategic partnership to research, develop and commercialize ibrexafungerp in the Greater China region JERSEY...

September 13, 2021September 13, 2021by In News
Post

Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming H.C. Wainwright 23rd Annual Global Investment Conference. Details of the Company’s participation are as follows: Conference: H.C. Wainwright 23rd...

September 9, 2021September 9, 2021by In News
Post

Nabriva and Vizient Enter into Agreement to Make XENLETA® (lefamulin) Available to Vizient’s Pharmacy Network Program

– Expands access to XENLETA for hospitalized patients with Community Acquired Bacterial Pneumonia (CABP) DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has entered into an...

September 9, 2021September 9, 2021by In News
Post

Iterum Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

DUBLIN, Ireland and CHICAGO, Sept. 08, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Corey Fishman, Chief Executive...

September 8, 2021September 8, 2021by In News
Post

SCYNEXIS to Participate in Upcoming Investor Conferences

SCYNEXIS to Participate in Upcoming Investor Conferences JERSEY CITY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Company will participate in the following virtual investor conferences in September....

September 8, 2021September 8, 2021by In News
Post

Lefamulin Receives Approval in Taiwan for Treatment of Community-Acquired Pneumonia

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner, Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. has received approval to market oral and intravenous (IV) formulations of...

September 8, 2021September 8, 2021by In News
Post

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting compounds designed to transform the standard of care for prevention and treatment of serious diseases, today announced that Jeffrey Stein, Ph.D., president and chief executive officer, will participate in two upcoming investor conferences: the H.C. Wainwright 23rd...

September 7, 2021September 7, 2021by In News
Post

Cidara Therapeutics to Host Research and Development Day

Virtual event will highlight the broad potential of the Cloudbreak® platform and the commercial potential for rezafungin Clinical thought leaders will highlight the risks of invasive fungal infections in cancer patients, and the unmet medical need in respiratory viral diseases Webinar to be held on Tuesday, September 21st at 10:00am ET SAN DIEGO, Sept. 02,...

September 2, 2021September 2, 2021by In News
Post

Cidara Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, and Shane Ward as Chief Legal Officer and Corporate Secretary

Appointments add two biotech industry veterans each with over two decades of experience to Company’s management team SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointments...

September 1, 2021September 1, 2021by In News
Post

Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, Sept. 01, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 32,130 ordinary shares of Nabriva Therapeutics as an inducement to three...

September 1, 2021September 1, 2021by In News